References
- Zymeworks and BeiGene announce license and collaboration agreement for Zymeworks’ HER2-Targeted therapeutic candidates, ZW25 and ZW49, in Asia-Pacific and research and license agreement for Zymeworks’ Azymetric™ and EFECT™ platforms globally . www.businesswire.com/news/home/20181127005311/en/Zymeworks-BeiGene-Announce-License-Collaboration-Agreement-Zymeworks%E2%80%99
- Generex Biotechnology expands medical device portfolio with acquisition of Olaregen Therapeutix Inc . www.businesswire.com/news/home/20181128005244/en/Generex-Biotechnology-Expands-Medical-Device-Portfolio-Acquisition
- Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea® . https://oasmia.com/en/press-release/oasmia-pharmaceutical-ab-announces-new-agreement-baxter-oncology-gmbh-global-commercial-manufacturing-apealea/
- Oasmia Pharmaceutical receives approval from European Commission for Apealea® (paclitaxel micellar) in the European Union . https://globenewswire.com/news-release/2018/11/22/1655521/0/en/Oasmia-Pharmaceutical-Receives-Approval-from-European-Commission-for-Apealea-paclitaxel-micellar-in-the-European-Union.html
- Tetra Bio-Pharma bolsters intellectual property position and product pipeline . https://tetrabiopharma.com/investors/press-releases/press-release-details/2018/Tetra-Bio-Pharma-Bolsters-Intellectual-Property-Position-and-Product-Pipeline/default.aspx
- Precision NanoSystems and Entos Pharmaceuticals sign license agreement for the use of the NanoAssemblr™ platform for scale-up and GMP manufacturing of nanomedicines . www.precisionnanosystems.com/our-company/news-room
- Insulet collaborates with Samsung to deliver Galaxy smartphone-controlled insulin pump delivery system . www.businesswire.com/news/home/20181107005538/en/Insulet-Collaborates-Samsung-Deliver-Galaxy-Smartphone-Controlled-Insulin
- Enable Injections enters into strategic partnerships with UCB and Apellis Pharmaceuticals . www.prnewswire.com/news-releases/enable-injections-enters-into-strategic-partnerships-with-ucb-and-apellis-pharmaceuticals-300748700.html
- Aerogen accelerates global growth with Temasek Investment . www.aerogen.com/aerogen-accelerates-global-growth-with-temasek-investment/
- FDA warns on pain drugs for implantable pumps . www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm625789.htm
- FDA Approves the ACTPen for Genentech’s Actemra, a single-dose, prefilled autoinjector for the treatment of rheumatoid arthritis, giant cell arteritis and two forms of juvenile arthritis . www.apnews.com/70efc5a9b5ec4d9ea0a586b7015dbe4f
- Aquestive Therapeutics launches SYMPAZAN™ (clobazam) oral film with widespread U.S. availability . https://aquestive.com/single-news?post=6851
- Aquestive Therapeutics announces U.S. Food and Drug Administration (FDA) approval for SYMPAZAN™ (clobazam) oral film . https://aquestive.com/single-news?post=6776
- Intellipharmaceutics announces FDA final approval of generic Effexor® XR . www.intellipharmaceutics.com/news-media/press-releases/detail/188/intellipharmaceutics-announces-fda-final-approval-of
- Exicure, Inc. provides update on corporate progress and third quarter 2018 financial results . www.businesswire.com/news/home/20181106005180/en/Exicure-Update-Corporate-Progress-Quarter-2018-Financial
- TriSalus Life Sciences’ Pressure-Enabled Drug Delivery (PEDD) significantly increased therapeutic effect of anti-CEA CAR-T in pancreatic cancer patients with liver metastases . www.businesswire.com/news/home/20181107005085/en/TriSalus-Life-Sciences%E2%80%99-Pressure-Enabled-Drug-Delivery-PEDD
- Kala Pharmaceuticals reports third quarter 2018 financial results . www.businesswire.com/news/home/20181108005277/en/Kala-Pharmaceuticals-Reports-Quarter-2018-Financial-Results
- Clearside Biomedical announces SAPPHIRE Phase III study of combination therapy in retinal vein occlusion did not meet its primary end point . http://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-announces-sapphire-phase-3-study
- Clearside Biomedical submits new drug application for XIPERE™ for the treatment of macular edema associated with uveitis . http://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-submits-new-drug-application-xiperetm
- Eyenovia initiates Phase III MicroStat program for pharmacologic mydriasis: enrolls first patient in MIST-1 study . http://ir.eyenoviabio.com/phoenix.zhtml?c=254685&p=irol-newsArticle&ID=2378160
- Pasquale LR Lin S Weinrab RN Tsai JC Kramm RL Ianchulev T . Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 μg daily microdose . Clin. Ophthalmol.12 ( 1 ), 2451 – 2457 ( 2018 ).
- Eyenovia announces publication of its PG21 Phase II trial results demonstrating robust IOP lowering effect and patient usability . http://ir.eyenoviabio.com/phoenix.zhtml?c=254685&p=irol-newsArticle&ID=2378597
- Pulmatrix announces positive final results from the Phase I/1b clinical trial of Pulmazol . https://ir.pulmatrix.com/2018-11-21-Pulmatrix-Announces-Positive-Final-Results-from-the-Phase-1-1b-Clinical-Trial-of-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole
- IntelGenx begins Montelukast Versafilm™ dosing in patients with mild to moderate Alzheimer’s Disease in Phase IIa study . www.intelgenx.com/investors/press-releases/press-release-details/2018/IntelGenx-Begins-Montelukast-VersaFilm-Dosing-in-Patients-with-Mild-to-Moderate-Alzheimers-Disease-in-Phase-2a-Study/default.aspx
- IntelGenx announces FDA’s acceptance of resubmission of new drug application for Rizaport® . www.intelgenx.com/investors/press-releases/press-release-details/2018/IntelGenx-Announces-FDAs-Acceptance-of-Resubmission-of-New-Drug-Application-for-RIZAPORT/default.aspx
- Lyndra Therapeutics reports positive results from Pharmacokinetics (PK) Study of its ultra-long-acting oral dosage form . www.businesswire.com/news/home/20181115005207/en/Lyndra-Therapeutics-Reports-Positive-Results-Pharmacokinetics-PK
- Than A Chenghao L Chang H et al. Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery . Nat. Commun.9 , 4433 ( 2018 ).
- Paczkowska M Mikolaj M Kinga S et al. Enhanced pharmacological efficacy of sumatriptan due to modification of its physicochemical properties by inclusion in selected cyclodextrins . Sci. Rep.8 , 1 – 13 , 16184 ( 2018 ).
- Ahmen OB Hermann L . Bacteria-mediated delivery of RNAi effector molecules against viral HPV16-E7 eradicates oral squamous carcinoma cells (OSCC) via apoptosis . Cancer Gene Ther.10.1038/s41417-018-0054-x ( 2018 ) [ Epub ahead of print ].
- Anselmo AC Gokarn Y Mitragotri S . Non-invasive delivery strategies for biologics . Nat. Rev. Drug Discov.18 , 19 – 40 ( 2019 ).
- Ultrasound releases drug to alter activity in targeted brain areas in rats . https://med.stanford.edu/news/all-news/2018/11/ultrasound-releases-drug-to-alter-activity-in-targeted-brain-area.html
- Yissum Announces new platform for 3D printing of personalized medicine . www.prnewswire.com/news-releases/yissum-announces-new-platform-for-3d-printing-of-personalized-medicine-300744535.html
- Magnetic nanosprings used as targeted drug delivery agents for anticancer therapy . www.news-medical.net/news/20181113/Magnetic-nanosprings-used-as-targeted-drug-delivery-agents-for-anticancer-therapy.aspx
- Harpoon Therapeutics Unveils ProTriTAC Platform: a novel, protease-activated T Cell engager platform designed to access a broad landscape of solid tumor targets . www.businesswire.com/news/home/20181109005371/en/Harpoon-Therapeutics-Unveils-ProTriTAC-Platform-Protease-Activated-Cell
- OcuMedic, Inc. Granted European patent for contact lens drug delivery system . www.businesswire.com/news/home/20181105005572/en/OcuMedic-Granted-European-Patent-Contact-Lens-Drug
- New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted . https://oasmia.com/en/press-release/new-u-s-patent-related-oasmia-pharmaceuticals-nanotechnology-platform-xr17-granted/